Navigation Links
Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide
Date:11/25/2013

DUBLIN, November 25, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/q99tkv/ziopharm) has announced the addition of the "Ziopharm Oncology's ZIO-201 - a stable formulation of palifosfamide" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


The rationale to develop a stable formulation of palifosfamide is strong: it is the active metabolite of ifosfamide, a well-established alkylating chemotherapy agent. Palifosfamide may spare patients from the toxicities of two other inactive ifosfamide metabolites while retaining its anti-tumor activity. A phase III trial of palifosfamide in first line soft tissue sarcoma (PICASSO III) is underway with progression-free survival results expected later this year. In this report, we review the evidence supporting palifosfamide's development, the likelihood of clinical trial success, key regulatory hurdles as well as the commercial opportunity.

Key Topics Covered:

INTRODUCTION

1. Sarcomas
2. Treatment and prognosis of soft tissue sarcoma
3. Treatment of advanced or metastatic soft tissue sarcoma



PALIFOSFAMIDE

1. Palifosfamide as a single-agent
2. Palifosfamide in combination with doxorubicin
3. Phase I
4. Phase II
5. On-going phase III
6. Phase III trial in small cell lung cancer



CLINICAL AND REGULATORY OPINION

1. The rationale supporting the development of palifosfamide
2. Ifosfamide is active in STS: what does this mean for palifosfamide?
3. Phase II trial of palifosfamide suggests antitumor activity
4. Palifosfamide offers a better safety profile than ifosfamide
5. Ziopharm initiate PICASSO III pivotal trial without FDA's SPA
6. The two regulatory approval pathways
7. Is palifosfamide eligible for Accelerated Approval?
8. Is PFS a validated surrogate for overall survival in randomized front-line STS cancer trials?
9. The Votrient Precedent - Full approval based on PFS
10. Will palifosfamide succeed in the PICASSO III trial?
11. Is the MATISSE phase III trial in SCLC likely to succeed?


MARKET OPPORTUNITY

1. Revenue projection in STS
2. Revenue projections in other indications
3. Competitive landscape



CONCLUSION

Companies Mentioned


- Threshold Pharmaceuticals
- Merck KgaA
- Eisai
- Zeltia
- JNJ
- Ariad Pharmaeuticals,Glaxo-Smith Kline



For more information visit http://www.researchandmarkets.com/research/q99tkv/ziopharm

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
2. EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease
3. Hoopes Vision Surgeon First in Utah to Implant New Light Adjustable Artificial Lens
4. Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine
5. European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
6. Long Term Follow Up Data On WEB Aneurysm Embolization System Demonstrate High Rate Of Stable Occlusion In Difficult To Treat Aneurysms
7. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
10. Maximum-Strength Formulation Offers Highest Concentration and Purity
11. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Ill. , Feb. 11, 2016  AbbVie, ... the AbbVie Rheumatology Scholarship, designed to provide financial ... disease as they pursue higher education goals. Fifteen ... for the 2016-2017 school year. The AbbVie Rheumatology ... Tracie Haas , vice president, corporate social responsibility, ...
(Date:2/11/2016)... Feb. 11, 2016  Community pharmacists can help improve ... the pharmacy through a custom-built medication synchronization program, Cardinal ... and owner at Schieber Family Pharmacy in ... a lot of patients enrolled in this medication synchronization ... a win for the patient, and it,s a win ...
(Date:2/11/2016)... , Feb. 11, 2016 Scientists from ... method that opens the door to genetic analysis ... have been impossible to isolate with 100 percent ... specific tumor types in various stages of development, ... of these cells that are clinically relevant, and ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... 12, 2016 , ... The Journal of Pain Research has seen ... SJR uses data taken from the Scopus database (Elsevier B.V.) and is a measure ... by the journal over a three year period and also the importance of the ...
(Date:2/11/2016)... ... 11, 2016 , ... The president released a FY 2017 budget request on ... more of the cost burden to military beneficiaries. , MOAA’s president, retired Air ... budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , ...
(Date:2/11/2016)... ... February 11, 2016 , ... Hall Integrative Health and ... for their simultaneous grand openings in March. All seven practices are set to ... wondering, is reversing diabetes possible? According to this 2011 CNN article it is ...
(Date:2/11/2016)... ... 2016 , ... Thermi™, a world leader in thermistor-regulated energy ... promotions of Allison Kelly to executive vice president of the company’s new North ... North American capital sales, and Wendy Oseas to vice president of global marketing. ...
(Date:2/11/2016)... ... 11, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health ... value-based health benefits program Connected Care, will discuss the challenges they faced (and ...
Breaking Medicine News(10 mins):